The PE Ratio as of September 2024 (TTM) for Xilio Therapeutics, Inc. (XLO) is -0.41

According to Xilio Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.41. This represents a change of -38.35% compared to the average of -0.67 of the last 4 quarters.

Xilio Therapeutics, Inc. (XLO) Historical PE Ratio (quarterly & annually)

How has XLO PE Ratio performed in the past?

The mean historical PE Ratio of Xilio Therapeutics, Inc. over the last ten years is -8.06. The current -0.41 PE Ratio has changed 408.92% with respect to the historical average. Over the past ten years (40 quarters), XLO's PE Ratio was at its highest in in the June 2020 quarter at -0.14. The PE Ratio was at its lowest in in the September 2020 quarter at -7.20.

Xilio Therapeutics, Inc. (XLO) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Xilio Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xilio Therapeutics, Inc. (XLO) Average PE Ratio

How has XLO PE Ratio performed in the past?

The current PE Ratio of Xilio Therapeutics, Inc. (XLO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Xilio Therapeutics, Inc. (XLO) PE Ratio vs. Peers

How is XLO’s PE Ratio compared to its peers?

Xilio Therapeutics, Inc.’s PE Ratio is greater than Connect Biopharma Holdings Limited (-3.00), greater than Tyra Biosciences, Inc. (-14.94), greater than RAPT Therapeutics, Inc. (-0.59), greater than Mineralys Therapeutics, Inc. (-4.63), less than Edgewise Therapeutics, Inc. (0), greater than Ikena Oncology, Inc. (-14.14), greater than Design Therapeutics, Inc. (-1.22), greater than Eliem Therapeutics, Inc. (-5.23), greater than Anebulo Pharmaceuticals, Inc. (-3.49), greater than AN2 Therapeutics, Inc. (-4.99), greater than Aerovate Therapeutics, Inc. (-0.47), greater than Adagene Inc. (-0.62), greater than Molecular Partners AG (-2.86), greater than MediciNova, Inc. (-2.67), greater than Champions Oncology, Inc. (-12.61), greater than Cyteir Therapeutics, Inc. (-7.94), greater than null (-3.52),

Build a custom stock screener for Xilio Therapeutics, Inc. (XLO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xilio Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xilio Therapeutics, Inc. (XLO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xilio Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.